Jubilant Life gets booster dose from US FDA

Jubilant Life Sciences has received approval from the US regulator for Irbesartan and Cetirizine Hydrochloride tablets used for treatment of hypertension and allergies respectively. It has received final nod from the US FDA for its abbreviated new drug application. The total market size for Irbesartan tablets is about $50 million/annum. The stock jumped sharply on Tuesday itself though the announcement came to the exchanges only after market hours.